Table 1.
Characteristics of AML patients
| Variables | Number (%) |
|---|---|
| Age | |
| ≤20 y | 5 (2.2) |
| 21‐40 y | 47 (20.8) |
| 41‐60 y | 79 (35.0) |
| 60‐90 y | 95 (42.0) |
| Gender | |
| Female | 113 (50.0) |
| Men | 113 (50.0) |
| WBC (cells/mm3) | 11 270.0 [31 00.0; 38 700.0]a |
| <50 000 | 183 (81.0) |
| ≥50 000 | 43 (19.0) |
| PLT (cells/mm3) | 36 500 [11 000.0; 77 000.0]a |
| <40 000 | 119 (52.7) |
| ≥40 000 | 107 (47.3) |
| Hgb (g/dL) | 8.73 [7.8; 10.2]a |
| <10 | 166 (73.5) |
| ≥10 | 60 (26.5) |
| LDH level (IU/L) | 688.5 [461.0; 1132.0]a |
| <600 | 96 (42.5) |
| ≥600 | 130 (57.5) |
| Blasts (in bone marrow, %) | 60.0 [40.0; 78.0]a |
| <70 | 138 (61.1) |
| ≥70 | 88 (38.9) |
| Cytogenetic risk | |
| Low risk (favorable prognostic) | 24 (10.6) |
| Intermediate | 123 (54.4) |
| High risk (adverse) | 57 (25.3) |
| Not available (NA) | 22 (9.7) |
| ECOG performance status | |
| 0 | 3 (1.3) |
| 1 | 36 (15.9) |
| 2 | 37 (16.4) |
| 3 | 91 (40.3) |
| 4 | 59 (26.1) |
| ECOG performance status | |
| ≤1 | 39 |
| ≥2 | 187 |
| AML subtype | |
| de novo AML | 182 (81.5) |
| Secondary AML | 40 (17.7) |
| Therapy related AML | 4 (1.8) |
| FLT3 status (ITD+D835) | |
| Absent | 182 (81.4) |
| Present | 42 (18.6) |
| FLT3‐ITD status | |
| Absent | 191 (84.5) |
| Present | 35 (15.5) |
| FLT3 D835 status | |
| Absent | 214 (94.7) |
| Present | 12 (5.3) |
| DNMT3A R882 status | |
| Wild‐type | 200 (88.5) |
| Mutant | 26 (11.5) |
| NPM1 c.863_864insTCTG status | |
| Wild‐type | 189 (83.6) |
| Mutant | 37 (16.4) |
| Treatment | |
| HD | 119 (52.7) |
| LD | 91 (40.3) |
| HD + HSCT | 16 (7.0) |
Abbreviations: AML, acute myeloid leukemia; ECOG, Eastern Cooperative Oncologic Group Scale; HD, high dose of chemotherapy; HSCT, hematopoietic stem cell transplantation; LD, low dose of chemotherapy; LDH, lactate dehydrogenase; PLT, platelet; WBC, white blood cell.
a
Median and interquartile range (percentile 25%; percentile 75%).